News | October 24, 2007

Cook to Introduce Stenting Kit, Lead Extraction Device

October 25, 2007 - Global Therapeutics, a Cook Medical company, said at TCT 2007 it will begin a clinical trial using AVI-5126, a next generation antisense drug. It will be included in a kit containing a bare metal stent and a site-specific catheter for drug delivery. In addition, Cook Medical has introduced a new lead extraction device named the “Evolution.”
Resten-P (AVI-5126), a drug developed by AVI BioPharma, Inc. (AVII) and licensed by Cook Medical, is a third-generation antisense agent that targets the key regulatory gene responsible for smooth muscle cell proliferation involved in cardiovascular restenosis. The drug will be part of a stenting kit that provides a bare cobalt chromium stent and a delivery catheter. The drug will be delivered separately from the stent.
“Cook has overcome the issues of higher rate of recoil associated with the cobalt chromium stents currently on the market. We plan to begin sales of our bare metal coronary stent system in Europe during the first quarter of 2008. Also, plans are in the works to begin a trial in the U.S. before mid-year 2008,” representatives from Global Therapeutics commented.
Another highlight was the anticipated introduction of Evolution, a new lead extraction device, designed to aid in the percutaneous removal of cardiac leads.

For more information:

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Sponsored Content | Videos | Stents Bifurcation| March 06, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent.
Overlay Init